The role of pemetrexed in the treatment of gastrointestinal malignancy

Clinical Colorectal Cancer

Volumn 4, Issue 3, 2004, Pages 190-195

  Hochster, Howard S ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 FU; Antifolate; Combination therapy; Gemcitabine; Methotrexate; Targeted therapy; Thymidylate synthase

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; PEMETREXED;

CLINICAL TRIAL; COLORECTAL TUMOR; HUMAN; PANCREAS TUMOR; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS; COLORECTAL NEOPLASMS; GLUTAMATES; GUANINE; HUMANS; PANCREATIC NEOPLASMS;

EID: 16544385662     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2004.n.019     Document Type: Review

References (32)

1. Meta-analysis Group: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced colorectal cancer meta-analysis project. J Clin Oncol 1992; 10:896-903.
2. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998; 16:301-308.
3. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-1418.
4. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
5. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355:1041-1047.
6. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
7. Rothenberg ML, Oza AM, Burger B, et al. Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin. Proc Am Soc Clin Oncol 2003; 22:252 (Abstract #1011).
8. Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an intergroup study. Proc Am Soc Clin Oncol 2003; 22:252 (Abstract #1009).
9. Tournigand C, Louvet C, Quinaux E, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol 2001; 20:124a (Abstract #494).
10. Cripps C, Burnell M, Jolivet J, et al. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study. Ann Oncol 1999; 10:1175-1179.
11. John W, Picus J, Blanke CD, et al. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: Results from a phase II study. Cancer 2000; 88:1807-1813.
12. Paulson R, Hainsworth J, Geyer C, et al. A phase II trial of MTA (multiple targeted antifolate, LY231514) in patients with 5-FU and irinotecan-refractory colorectal cancer. Proc Am Soc Clin Oncol 1999; 18:297a (Abstract #1140).
13. Misset JL, Gaemlin E, Campone M, et al. Pemetrexed/oxaliplatin (LOHP) combination: Results of a phase I study in metastatic solid tumors. Clin Pharmacol 2002; 21:107a (Abstract #427).
14. Atkins JN, Jacobs S, Wieand S, et al. Pemetrexed and oxaliplatin for first-line treatment of patients with advanced colorectal cancer: A phase II trial of the NSABP foundation research program. Proc Am Soc Clin Oncol 2003; 22:276 (Abstract #1108).
15. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15:2403-2413.
16. Gandhi V, Plunkett W, Du M, et al. Prolonged infusion of gemcitabine: Clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 2002; 20:665-673.
17. Tempero M, Plunkett W, Ruiz Van Haperen V, et. al. Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-minute Infusion and Fixed Dose Rate Infusion in Patients with Pancreatic Adenocarcinoma. J Clin Oncol 2003; 21:3402-3408.
18. Rinaldi DA, Kuhn JG, Burris HA, et al: A phase I evaluation of multitargeted antifolate (MTA, LY231514) administered every 21 days, utilizing modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999; 44:372-380.
19. Miller KD, Picus J, Blanke C, et al. Phase II study of the multi-targeted antifolate LY231514 (Alimta, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 2000; 11:101-103.
20. Adjei AA, Erlichman C, Sloan JA, et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000; 18:1748-1757.
21. Kindler HL, Dugan W, Hochster H, et al. Clinical outcome in patients (pts) with advanced pancreatic cancer treated with pemetrexed/gemcitabine Proc Am Soc Clin Oncol 2002; 21:125a (Abstract #499).
22. Richards DA, Kindler HL, Oettle H, et al. A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. Presented as a late-breaking abstract at the 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8 2004; New Orleans, LA. Abstract #4007.
23. Van Cutsem E, van deVelde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22:1430-1438.
24. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20:3270-3275.
25. Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21:3296-3302.
26. Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19:3447-3455.
27. Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first-line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87:161-167.
28. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002; 94:902-910.
29. Heinemann V, Quietzsch D, Giesler F, et al. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proc Am Soc Clin Oncol 2003; 22:250 (Abstract #1003).
30. Rocha Lima CMS, Rotche R, Jeffery M, et al. A randomized phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy. Proc Am Soc Clin Oncol 2003; 22:251 (Abstract #1005).
31. Louvet C, Labianca R, Hammel P, et al. GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non-resectable pancreatic adenocarcinoma: final results of the GERCOR/GISCAD Intergroup Phase III. Proc Am Soc Clin Oncol (post-meeting edition) 2004; 22 (Abstract #4008).
32. Cheverton P, Friess H, Andras C, et al. Phase III results of exactecan (DX-8951f) versus gemcitabine (Gem) in chemotherapynaive patients with advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol (post-meeting edition) 2004; 22 (Abstract #4005).